NewAmsterdam Pharma Company NAMS EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from NewAmsterdam Pharma Company’s reported figures.
Based on trailing twelve months.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's EBITDA margin?
- NewAmsterdam Pharma Company (NAMS) reported EBITDA margin of -952.6% in Q1 2026.
- How has NewAmsterdam Pharma Company's EBITDA margin changed year-over-year?
- NewAmsterdam Pharma Company's EBITDA margin decreased by 136.9% year-over-year, from -402.2% to -952.6%.
- What is the long-term trend for NewAmsterdam Pharma Company's EBITDA margin?
- Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's EBITDA margin has grown at a 561.9% compound annual growth rate (CAGR), from -3.5% to -1,001.9%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.